Relationship between sarcopenia/myosteatosis and frailty in hospitalized patients with cirrhosis: a sex-stratified analysis

Hongjuan Feng*, Xiaoyu Wang*, Lihong Mao*, Zihan Yu, Binxin Cui, Lin Lin, Yangyang Hui, Xingliang Zhao, Xin Xu, Xiaofei Fan, Bangmao Wang, Qingxiang Yu, Kui Jiang and Chao Sun

Abstract

Background: Previous studies have shown that sarcopenia appears to be a significant contributor to physical frailty among outpatients with cirrhosis. However, the evidence is scant regarding the relationship between sarcopenia and multi-dimensional frailty among inpatients. We aimed to investigate the potential contribution of sarcopenia to frailty in hospitalized patients with sex-dependent manner.

Methods: This cohort enrolled consecutive cirrhotics. Muscle quantity and quality were assessed using the computed tomography-based skeletal muscle index (SMI) and intramuscular adipose tissue content, respectively. Frailty phenotype was clarified by a self-reported Frailty Index. Multiple linear regression determined the association between sarcopenia and frailty phenotype.

Results: A total of 202 cirrhotic patients with 48.5% male were included. The median Frailty Index was 0.13, rendering 17.3% subjects as frail. Among the 16 frail men, 68.8% had sarcopenia and 62.5% exhibited myosteatosis. In contrast, among the 19 frail women, 26.3% had sarcopenia and 15.8% exhibited myosteatosis. Frail patients had a significantly lower median SMI (42.80 cm²/m²) compared with those with pre-frailty (48.23 cm²/m²) and with robust status (50.82 cm²/m²) in the male but not the female group. In male patients, multivariate linear regression implicated age ($\beta = 0.330, \ p < 0.001$), SMI ($\beta = -0.260, \ p < 0.001$), albumin ($\beta = -0.245, \ p = 0.005$), and sodium ($\beta = -0.179, \ p = 0.037$) as independent risk factors for frailty.

Conclusion: Sarcopenia is associated with multi-dimensional frailty in male patients with cirrhosis. It is tempting to incorporate sex-specific intervention with the purpose of mitigating frailty among inpatients.

Keywords: cirrhosis, frailty, myosteatosis, sarcopenia, sex difference

Received: 19 February 2021; revised manuscript accepted: 3 June 2021.
in a cohort of 291 cirrhotic outpatients, sarcopenia was associated with approximately two-fold increased odds of being frail. However, two-thirds of frail male cirrhotics had sarcopenia, whilst only 25% of frail female represented sarcopenia. It is not surprising that foregoing studies showed more overlap with sarcopenia since their modalities employed a physical frailty definition with low handgrip strength as part of diagnostic criteria. As a matter of fact, the construct of frailty goes beyond physical dimensions and embraces psychological and social constituents as well, including cognitive function and social support. Taken together, it is an unmet need to explore the relationship between sarcopenia and frailty phenotype determined by multiple metrics.

More recently, we have developed a self-reported Frailty Index for prognostication, which sounds more applicable, in comparison with physical tests, among severely frail cirrhotics with mobilizing difficulty. The proposed scale allows us to converge on a relatively parsimonious number of tests relevant to physical frailty. Herein we aimed to investigate the association between sarcopenia and multi-dimensional frailty in hospitalized patients with cirrhosis. Additionally, in-depth sex-dependent disparities were illuminated.

**Methods**

**Study cohort**

A cohort of adult patients with cirrhosis was consecutively enrolled in the Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital (TJMUGH) between March 2017 and November 2019. Written informed consent was obtained from all participants. The diagnosis of liver cirrhosis was made in terms of medical history, clinical, laboratory, and imaging results, as well as transient elastography or biopsy. The exclusion criteria were as follows: (i) primary liver tumors or extrahepatic cancers; (ii) acute on chronic liver failure upon admission; (iii) presence of severe hepatic encephalopathy (as recognized by a time to complete a numbers connection test of more than 120 s); (iv) liver transplantation; (v) refusal of follow-up; (vi) more than 26 empty items in questionnaire. A total of 202 patients with cirrhosis were left for final analysis (Supplemental material Figure S1 online). The present study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of TJMUGH (2016-033).

**Frailty Index assessment**

As deciphered in our previous work, Frailty Index derives from a self-reported scale, Carolina Frailty Index (CFI). CFI is a questionnaire consisting of 36 items regarding various components, such as instrumental activities of daily living, physical function, unintentional weight loss, exhaustion, depression, and social activities. Taking account of the pathophysiological nature of cirrhosis, we modulated the original CFI and obtained a new Frailty Index (Supplemental Table S1). A questionnaire which is fulfilled with 10 items or more will be regarded as valid. The Frailty Index is determined according to the score that patients retrieve from the total points of the questionnaire. For instance, a patient who gets 12 points after finishing all 36 items has a Frailty Index of 0.33 (12/36); a patient who gets six points after finishing 12 items of the questionnaire has a Frailty Index of 0.50 (6/12). In terms of quartile, we defined the Frailty Index thus: less than 0.07 as robust, 0.07–0.38 as pre-frail, and more than 0.38 as frail. Furthermore, we collected the Frailty Index questionnaire soon after (within 48 h) the first admission to our department.

**Sarcopenia and myosteatosis evaluation**

A spectral computed tomography (CT) scanner (Discovery 750 HD 64-row, General Electric Company, Boston, USA) was applied to obtain all CT imaging. Skeletal muscle and adipose tissue at the third lumbar vertebra (L3) level were measured by using non-commercial software based on Matlab version R2010a (Mathworks Inc., Natick, MA, USA). Skeletal muscle area covered the psoas, erector spinae, quadratus lumborum, transversus abdominis, external and internal obliques, and rectus abdominis muscles. Tissue-specific Hounsfield unit (HU) thresholds were adopted to discriminate tissue types. The CT thresholds were −29 to 150 HU for quantifying skeletal muscle and −190 to −30 HU for subcutaneous adipose tissue and visceral adipose tissue. The skeletal muscle index (SMI) was defined according to our previous publication as a SMI <46.96 cm²/m² for male
and SMI < 32.46 cm²/m² for female. A weaker correlation has been reported between sarcopenia and various adverse outcomes in female. Thus we hypothesized that muscle quality would be more closely relevant to frailty phenotype. Accordingly, the muscle quality was determined by intramuscular adipose tissue content (IMAC) at the L3 level, whose efficacy and feasibility has been validated by us and others. IMAC was calculated by dividing the CT attenuation of the multifidus muscles (HU) by that of subcutaneous adipose tissue (HU). Higher IMAC reveals a greater amount of fat infiltration in muscle tissue and, therefore, a lower quality of muscle (myosteatosis). Moreover, the value of IMAC is normalized to the value of subcutaneous fat individually, and it is not influenced by the CT system or scanning conditions. Collectively, we assume that this indicator could more sensitively reflect skeletal muscle quality. The sex-specific cut-off values for defining myosteatosis were IMAC > -0.44 in male and > -0.37 in female, respectively.

**Statistical analysis**

Data were expressed as mean ± standard deviation, median [interquartile range (IQR)], simple frequency or proportion (%) as appropriate. Continuous data were compared using an independent Student’s t test or the Mann–Whitney U test. Categorical variables were compared by χ² test or Fisher’s exact test. Multiple comparisons were performed by using Kruskal–Wallis test with Dunn’s post hoc test. Correlations were evaluated by the Spearman’s correlation coefficient (r). The univariate analysis accounted for the correlation existing between demographic/clinical data, body composition parameters, and Frailty Index. Multivariate linear regression analysis was then used to identify the independent factors related to frailty phenotype. Of note, we selected to examine skeletal muscle metrics as continuums without dichotomization to better understand the relationship of skeletal muscle measures without making erroneous assumptions with respect to cutoff points. We set statistical significance at p < 0.05. All statistical analyses were carried out using SPSS 21.0 (IBM, New York, NY, USA) or Graphpad Prism 8.0.1 (La Jolla, CA, USA).

**Results**

**Patients’ characteristics**

The baseline demographic and laboratory data are presented in Table 1. A total of 202 patients (male: n = 98, 48.5%) with a median age of 63 years (IQR, 55–68) were recruited to the study. The primary etiology of cirrhosis was hepatitis B virus/hepatitis C virus in 21.8%, alcoholism/non-alcoholic fatty liver disease in 25.2%, and autoimmune liver disease in 20.8%. The median model for end-stage liver disease (MELD) score upon admission was 10 points (IQR, 8–13). Seventy-seven patients were classified as Child–Turcotte–Pugh (CTP)-A, 108 as CTP-B and 17 as CTP-C.

The median Frailty Index was 0.13 (IQR, 0.06–0.30). Thirty-five (17.3%) subjects were classified as frail. The distribution of frailty was even between male and female patients (16.3% versus 18.3%, p = 0.853). The median SMI was 44.2 cm²/m², and 30.2% of patients showed sarcopenia according to our proposed criteria. On the contrary, 69.8% (141/202) of patients were diagnosed as non-sarcopenia. The median IMAC was -0.50, and 18.8% of recruited patients (38/202) exhibited myosteatosis. In contrast, 81.2% (164/202) of subjects were categorized into the non-myosteatosis group.

**Overlap between sarcopenia, myosteatosis, and frailty phenotype**

Relationships between sarcopenia, myosteatosis, and frailty overall and separately for male and female are detailed in Figure 1 and Supplemental Figure S2. In the entire cohort, 16 (7.9%) met the criteria for both sarcopenia and frailty, and 13 (6.4%) met the criteria for both myosteatosis and frailty. In male patients, among the 16 patients who were frail, 68.8% also had sarcopenia and 62.5% had myosteatosis. In female patients, among the 19 patients who were frail, 68.8% also had sarcopenia and 62.5% had myosteatosis. In male patients, among the 16 patients who were frail, 68.8% also had sarcopenia and 62.5% had myosteatosis. In female patients, among the 19 patients who were frail, 68.8% also had sarcopenia and 62.5% had myosteatosis.

**Cross-sectional association between sarcopenia and domains of the Frailty Index**

Given that the depiction of frailty is multifaceted, we further performed secondary analyses about the association between sarcopenia and multiple components of the Frailty Index in the entire
Table 1. Baseline characteristics of the entire cohort, categorized by sex and multi-dimensional frailty phenotype.

|                        | All       | Male      | Female     | Frailty§  | Not frailty | p      | Male      | Frailty§  | Not frailty | p      |
|------------------------|-----------|-----------|------------|-----------|-------------|--------|-----------|-----------|-------------|--------|
|                        | All N = 202 | 98        | 104        | n = 16    | n = 82      | p      | n = 19    | n = 85    | p           |        |
| Age, years             |           |           |            |           |             |        |           |           |             |        |
|                        | 63 [55, 68]| 67 [62, 76]| 58 [52, 66]|           | 0.004       |        | 69 [63, 74]| 63 [57, 68]| 0.077       |
| BMI, kg/m²              |           |           |            |           |             |        |           |           |             |        |
|                        | 23.7 [20.7, 26.5]| 24.7 [18.8, 26.7]| 24.5 [22.5, 27.7]|           | 0.484       |        | 21.5 [19.7, 23.9]| 22.9 [19.8, 25.4]| 0.418       |
| VATI, cm²/m²            |           |           |            |           |             |        |           |           |             |        |
|                        | 46.0 [29.4, 67.0]| 52.4 [52.5, 64.9]| 49.7 [33.2, 71.4]|           | 0.743       |        | 31.6 [25.6, 61.7]| 41.8 [25.8, 64.6]| 0.739       |
| SMI, cm²/m²             |           |           |            |           |             |        |           |           |             |        |
|                        | 44.2 [38.7, 50.8]| 42.6 [30.8, 49.9]| 48.4 [42.6, 55.8]|           | 0.042       |        | 42.6 [36.7, 49.4]| 40.1 [35.9, 45.6]| 0.176       |
| Sarcopenia§ (%)         |           |           |            |           |             |        |           |           |             |        |
| Yes                    | 61 [30.2] | 11 [68.8] | 29 [35.4]  |           | 0.024       |        | 5 [26.3]  | 16 [18.8] | 0.529       |
| No                     | 141 [69.8]| 5 [31.3]  | 53 [64.6]  |           |             |        | 14 [73.7] | 69 [81.2] |            |
| IMAC                   | −0.50 [−0.61, −0.42]| −0.42 [−0.57, −0.38]| −0.53 [−0.64, −0.45]| 0.010 | −0.48 [−0.61, −0.39]| −0.5 [−0.60, −0.40]| 0.512 |
| Myosteatosis§ (%)       |           |           |            |           |             |        |           |           |             |        |
| Yes                    | 38 [18.8] | 10 [62.5] | 13 [15.8]  |           | 0.001       |        | 3 [15.8]  | 12 [14.1] | 0.546       |
| No                     | 164 [81.2]| 6 [37.5]  | 69 [84.2]  |           |             |        | 16 [84.2] | 73 [85.9] |            |
| MELD score             | 10.0 [8.0, 13.0]| 11.6 [8.0, 14.7]| 9.1 [6.8, 12.0]| 0.207 | 13.0 [10.0, 17.0]| 10.0 [8.0, 12.0]| 0.011 |
| Albumin, g/l           | 28 [25, 33]| 26 [22, 28]| 29 [25, 34]|           | 0.029       |        | 26 [20, 31]| 29 [25, 33]| 0.115       |
| INR                    | 1.26 [1.17, 1.44]| 1.35 [1.30, 1.52]| 1.29 [1.20, 1.43]| 0.167 | 1.27 [1.13, 1.44]| 1.21 [1.11, 1.39]| 0.578 |
| Total bilirubin, µmol/l| 21.6 [14.6, 41.7]| 32.2 [19.8, 52.3]| 19.5 [13.8, 43.3]| 0.059 | 30 [21.9, 57.7]| 20.6 [13.8, 37.2]| 0.041 |
| Creatinine, µmol/l     | 59 [51, 77]| 83 [61, 105]| 66 [57, 80]|           | 0.094       |        | 62 [52, 102]| 52 [43, 59]| 0.058       |
| Sodium, mmol/l         | 140 [137, 142]| 134 [129, 139]| 140 [138, 142]| <0.001 | 139 [136, 142]| 140 [137, 142.5]| 0.903 |
| ALT, U/l               | 24.0 [15.8, 37.0]| 18 [13, 21]| 26 [17, 44]|           | 0.020       |        | 17 [13, 27]| 25 [17.5, 37]| 0.161       |
| ALP, U/l               | 89.5 [67.8, 127.5]| 87.5 [65.8, 109.7]| 83 [65.6, 115.8]| 0.659 | 105.7 [72, 158]| 100 [68, 141]| 0.755 |
| Frailty Index           | 0.13 [0.06, 0.30]| 0.46 [0.44, 0.51]| 0.08 [0.04, 0.17]| <0.001 | 0.49 [0.42, 0.53]| 0.11 [0.04, 0.20]| <0.001 |
### Table 1. (Continued)

|                | All   | Male          | Female        |               |               |               |               |
|----------------|-------|---------------|---------------|---------------|---------------|---------------|---------------|
|                | \(N=202\) | \(n=98\)     | \(n=104\)     | Frailty\(^{\dagger}\) | Not frailty \(n=82\) | \(p\) | Frailty\(^{\dagger}\) | Not frailty \(n=85\) | \(p\) |
| CTP (\%)       |       |               |               |               |               |               |               |
| A              | 77 (38.1) | 4 (35.0) | 35 (42.7) | 0.329 | 4 (21.1) | 34 (40.0) | 0.004 |
| B              | 108 (53.5) | 9 (56.3) | 39 (47.6) |               | 11 (57.9) | 49 (57.6) |               |
| C              | 17 (8.4) | 3 (18.8) | 8 (9.8) |               | 4 (21.1) | 2 (2.4) |               |
| Etiology (%)   |       |               |               |               |               |               |               |
| HBV/HCV        | 44 (21.8) | 3 (18.8) | 25 (30.5) | 0.337 | 1 (5.3) | 15 (17.6) | 0.230 |
| Alcohol        | 51 (25.2) | 6 (37.5) | 34 (41.5) |               | 1 (10.5) | 10 (11.8) |               |
| AILD           | 42 (20.8) | 3 (18.8) | 5 (6.1) |               | 9 (47.4) | 25 (29.4) |               |
| Biliary        | 10 (5.0) | 0 (0) | 0 (0) |               | 0 (0) | 10 (11.8) |               |
| Other          | 55 (27.2) | 4 (25.0) | 18 (22.0) |               | 8 (42.1) | 25 (29.4) |               |
| Ascites (%)    |       |               |               |               |               |               |               |
| Yes            | 110 (54.5) | 14 (87.5) | 39 (47.6) | 0.005 | 16 (84.2) | 41 (48.2) | 0.005 |
| No             | 92 (45.5) | 2 (12.5) | 43 (52.4) |               | 3 (15.8) | 44 (51.8) |               |

Data are expressed as median (interquartile range), simple frequency or proportion (%). \(p\) values are derived from the Mann–Whitney \(U\) test or Fisher’s exact test.

\(^{\dagger}\)We defined the Frailty Index thus: less than 0.07 as robust, 0.07–0.38 as pre-frail, and more than 0.38 as frail. Sarcopenia was defined as a SMI < 46.96 cm\(^2\)/m\(^2\) for male and SMI < 32.46 cm\(^2\)/m\(^2\) for female. Myosteatosis was defined as an IMAC > -0.44 in male and > -0.37 in female.

\(^{\ddagger}\)Dry weight was implemented for calculating BMI. The dry weight was determined by subtracting 5% for mild ascites, 10% for moderate ascites, and 15% for bulky ascites for patients with ascites and edema, and 5% of body weight was subtracted for patients with peripheral edema.

AILD, auto-immune liver disease; ALP, alkaline phosphatase; ALT, alanine aminotransferase; BMI, body mass index; CTP, Child-Turcotte-Pugh class; HBV, hepatitis B virus; HCV, hepatitis C virus; IMAC, intramuscular adipose tissue content; INR, international normalized ratio; MELD, model for end-stage liver disease; SMI, skeletal muscle index; VATI, visceral adipose tissue index.
cohort. Our results indicated that the proportions of sarcopenic patients are significantly higher ($p < 0.05$) across several components of the Frailty Index such as telephone, transport, housekeeping, finance management, and self-reported health (Figure 2 and Supplemental Figure S3).

**Pairwise correlations between SMI, IMAC, and the Frailty Index**

In the entire population, we observed no correlation between SMI and Frailty Index with a borderline significance ($r_s = -0.136, p = 0.053$) [Figure 3(a) to (c)]. When stratified by sex, a slightly inverse correlation was present between decreased SMI and high Frailty Index in male patients ($r_s = -0.280, p = 0.005$) but not female ($r_s = 0.042, p = 0.675$). Similarly, no significant correlation was found between IMAC and Frailty Index in all patients ($r_s = 0.183, p = 0.009$) [Figure 3(d) to (f)]. In contrast, a positive correlation was present between increased IMAC and high Frailty Index in male patients ($r_s = 0.238, p = 0.018$) but not female ($r_s = 0.123, p = 0.213$).

**Figure 1.** Venn diagram illustrating the overlap between sarcopenia, myosteatosis, and multi-dimensional frailty (absolute number of each subset).

**Figure 2.** Comparisons of cirrhotic patients with some domains of the Frailty Index by the presence of sarcopenia ($p < 0.05$). $\chi^2$ test or Fisher’s exact test were performed as appropriate.
Comparison of SMI/IMAC between robust, pre-frailty, and frailty patients

In male patients, subjects with frailty had a significantly lower median SMI [42.80 cm²/m² (IQR, 32.8–49.5)] compared with those with pre-frailty [48.23 cm²/m² (IQR, 42.4–55.1)] and with robust phenotype [50.82 cm²/m² (IQR, 42.8, 61.6); p = 0.023] (Figure 4). Furthermore, male cirrhotics with frailty also represented a significantly higher median IMAC [−0.42 (IQR, −0.50, −0.38)] in comparison with those with pre-frailty [−0.52 (IQR, −0.63, −0.44)] and with robust phenotype [−0.56 (IQR, −0.64, −0.48); p = 0.004]. However, no difference regarding SMI or IMAC was found in female patients with cirrhosis.

Sex-stratified comparison of sarcopenia, myosteatosis, and biochemical tests between frail and non-frail patients

In male patients, frail subjects were more likely to be older (67 vs. 58 years, p = 0.004) in comparison with non-frail counterparts. Frail patients had
lower albumin (26 vs. 29 g/l, p = 0.029) and lower serum sodium (134 vs. 140 mmol/l, p < 0.001). Frail patients had higher incidence of sarcopenia (68.8 vs. 35.4%, p = 0.024) and myosteatosis (62.5 vs. 15.8%, p = 0.001). Correspondingly, frail patients exhibited lower SMI (42.6 vs. 48.4 cm²/m², p = 0.042) and higher IMAC value (−0.42 vs. −0.53, p = 0.010). However, there was no significant difference in body mass index (BMI), MELD, CTP, and etiology.

In female patients, frail subjects had higher median MELD (13 vs. 10, p = 0.011) and were more likely categorized as CTP-B and C (p = 0.004). However, patients with frailty and without frailty had similar age, BMI, and etiology. Of note, there was no significant difference with respect to SMI/IMAC values or incidence of sarcopenia/myosteatosis.

**Table 2. Univariate and multivariate linear regression for Frailty Index in male patients with cirrhosis.**

| Variables         | Univariate analysis | Multivariate analysis |
|-------------------|---------------------|-----------------------|
|                   | β       | 95% CI       | p        | β       | 95% CI       | p        |
| Age, years        | 0.436   | (0.254, 0.619) | <0.001  | 0.330   | (0.159, 0.500) | <0.001  |
| SMI, cm²/m²       | -0.335  | (-0.526, -0.144) | 0.001  | -0.260  | (-0.428, -0.092) | 0.003  |
| IMAC              | 0.120   | (-0.081, 0.321) | 0.239  |         |          |          |
| Albumin, g/l      | -0.319  | (-0.511, -0.127) | 0.001  | -0.245  | (-0.413, -0.077) | 0.005  |
| ALT, U/l          | -0.229  | (-0.426, -0.032) | 0.023  |         |          |          |
| Creatinine, μmol/l| 0.167   | (-0.032, 0.367) | 0.099  |         |          |          |
| Sodium, mmol/l    | -0.282  | (-0.476, -0.088) | 0.005  | -0.179  | (-0.347, -0.011) | 0.037  |
| Ascites, yes or no| 0.258   | (0.062, 0.454) | 0.010  |         |          |          |

β indicates standardized coefficient of univariate and multivariate linear regression.
ALT, alanine aminotransferase; CI, confidence interval; IMAC, intramuscular adipose tissue content; SMI, skeletal muscle index.

In this cohort of 202 cirrhotic patients, we showed an estimated prevalence of frailty in 17.3% subjects, which is comparable to previous reports citing rates of 17–19%. Intriguingly, we found that significant relationships between SMI (indicator of sarcopenia)/IMAC (indicator of myosteatosis) and frailty phenotype were exclusively expressed in male patients with cirrhosis. Subsequent multiple regression analysis implicated a strong association between sarcopenia and frailty among males. Approximately 70% of frail male subjects exhibited concomitant muscle wasting, whilst this proportion was only 26.3% in female. These findings substantially unravel varying impacts of sarcopenia on multi-dimensional frailty in the context of sex difference, raising awareness of sex-specific therapeutic intervention in the clinical practice.

**Discussion**

In male patients, our univariate linear regression analysis implicated that age (β coefficient = 0.436, p < 0.001), SMI (β = −0.335, p = 0.001), albumin (β = −0.245, p = 0.005) and sodium (β = −0.179, p = 0.037) were independent risk factors for frailty phenotype as determined by the Frailty Index.

In female patients, frail subjects had higher median MELD (13 vs. 10, p = 0.011) and were more likely categorized as CTP-B and C (p = 0.004). However, patients with frailty and without frailty had similar age, BMI, and etiology. Of note, there was no significant difference with respect to SMI/IMAC values or incidence of sarcopenia/myosteatosis.

**Relationship between sarcopenia, myosteatosis, and the Frailty Index in male**

In male patients, our univariate linear regression analysis implicated that age (β coefficient = 0.436, p < 0.001), SMI (β = −0.335, p = 0.001), albumin (β = −0.245, p = 0.005) and sodium (β = −0.179, p = 0.037) were independent risk factors for frailty phenotype as determined by the Frailty Index. Subsequent multiple regression analysis implicated a strong association between sarcopenia and frailty among males. Approximately 70% of frail male subjects exhibited concomitant muscle wasting, whilst this proportion was only 26.3% in female. These findings substantially unravel varying impacts of sarcopenia on multi-dimensional frailty in the context of sex difference, raising awareness of sex-specific therapeutic intervention in the clinical practice.
causative effect. Souza et al.29 found that frailty was associated with myosteatosis in a setting of 184 obese patients with colorectal cancer. In patients with hepatocellular carcinoma, frailty/pre-frailty was an independent predictor for muscle atrophy and Liver Frailty Index was inversely correlated with SMI.30 Although sarcopenia is linked with frailty, Bhanji et al.31 demonstrated that these entities occur with differing prevalence as well as distinct impacts on outcomes in wait-listed patients. Notably, a pioneer work conducted by Fozoun et al.7 intended to quantify the contribution of sarcopenia to the frail phenotype, and highlight the importance of sex-stratified analysis. Moreover, the authors demonstrated that it is imperative to verify their observations in hospitalized cirrhotics and to take consideration of perspectives of frailty other than physical construct. Therefore, these concerns arouse scientific endeavor for performing in-depth analyses in our study cohort. Intriguingly, our results indicated that sarcopenic patients are more prevalent across several components of the Frailty Index, including instrumental activities of daily living, physical function, and self-reported health. We believe this finding is reasonable and informative, since mounting data have confirmed that sarcopenia is closely associated with disability, functional decline, and poor physical performance in geriatrics and hepatology medical fields.32–34

Congruent with prior work, our results implicated a sex disparity with respect to relationship between sarcopenia and frailty.7 An open question remains of why the observed alterations were more profound in male. Actually, frailty patients are always having endocrine changes, such as reduced concentrations of testosterone.12 It has been suggested that testosterone significantly decreases in the cirrhotic male.35 On the other hand, accumulating data have indicated sex-specific differences in muscle homeostasis. Correspondingly, androgens might represent dominant sex steroids regulating muscle homeostasis in male.36 Low testosterone levels are evidenced to elicit a decrease in muscle mass and strength in male.37,38 Collectively, hormonal difference between sexes might partially explain the predisposition of sarcopenic male with cirrhosis to frailty phenotype.

How might sarcopenia result in a self-reported frailty phenotype in terms of the Frailty Index, which embraces cognitive, social, as well as emotional aspects? We offer a probable mechanism underlying this pathway. A hospitalized patient with cirrhosis is always prone to chronic inflammation and malnutrition status.39 Inflammation is proved as a potential contributor to frailty directly by affecting muscle protein synthesis and degradation, and indirectly by influencing important metabolic pathways.40,41 As a matter of fact, the original report using CFI (where our Frailty Index comes from) showed a significant positive correlation between CFI and neutrophil-to-lymphocyte ratio (NLR) \( r_s = 0.22, p = 0.025 \).42 In particular, our group clarified that high NLR was positively correlated with the expression of IL-6 \( (r_s = 0.39, p < 0.001) \) and IL-8 \( (r_s = 0.35, p < 0.001) \) in cirrhotics.43 Notably, malnutrition is another common complication of cirrhosis characterized by reduced muscle/adipose quantity, increased pro-inflammatory cytokines, and anorexia.35 This entity could be reversed with nutrition supplementation, slowing its progression towards sarcopenia.44 The overlap between frailty and malnutrition comprises reduced physical and cognitive function, and association with impaired clinical outcomes.45 Taken together, the common mechanism underpinning the occurrence and development of two linked entities known as sarcopenia and frailty might partially be responsible for our discoveries.

We acknowledge the following limitations to our study. First, due to the nature of an observational study, we just demonstrate an association between sarcopenia and frailty phenotype in male cirrhotics. In other words, it is undetermined whether alterations in muscle compartment are a cause, an aggravating factor, a consequence of the ongoing pathology, or an epiphenomenon reflecting the general poor condition of patients with cirrhosis.46 Second, we were unable to screen/assess nutrition status, sex steroid, and cytokines in the enrolled cohort, thus the potential role of these factors remains speculative. Third, we were lacking internal validation with respect to the proposed Frailty Index for generalizability in other populations. Further multi-center investigations are warranted to validate our findings. However, this single-center index appears to be a pivotal step to conceptual construct and clinical implication of multi-dimensional frailty in daily practice. Last, we excluded patients with severe hepatic encephalopathy, which might give rise to selection bias. However, taking account of limited applicability of physical metrics among inpatients and cognitive frailty likely prognosticating the prognosis in
cirrhosis,\textsuperscript{47,48} it is suitable for us to employ a broadened conceptual frailty phenotype.

Despite these limitations, this study is the first to highlight the close relationship between sarcopenia and multi-dimensional frailty in hospitalized cirrhosis. Our estimation of frailty phenotype derives from a well-validated self-reported Frailty Index for predicting all-cause mortality. Furthermore, the sex distribution is even in the cohort, which facilitates fully sex-stratified analyses. In conclusion, our findings implicate that sarcopenia is strongly associated with multi-dimensional frailty among male cirrhotic inpatients. It is tempting to incorporate sex-specific treatment with the purpose of mitigating frailty.

**Acknowledgement**
We thank all nurses who took part in the present study.

**Author contributions**
H.-J.F., X.-Y.W., L.-H.M. and C.S. designed the study, analyzed the data, and prepared the original draft. Z.-H.Y., B.-X.C. and L.L. conducted the study and edited the manuscript. Y.-Y.H., X.-L.Z., X.X. and X.-F.F. analyzed the data and reviewed the manuscript. B.-M.W. collected the data and conducted statistical analysis. Q.-X.Y., K.J. and C.S. designed and monitored the study and made critical revisions of the manuscript. All authors have approved the final draft submitted.

**Funding**
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was partly supported by the National Natural Science Foundation of China (grant 81800531 to X.-L.Z. and grant 81900487 to X.X.) and by the Science and Technology Program of Tianjin (Grant 19ZD01SY00020 to K.J.).

**Conflict of interest statement**
The authors declare that there is no conflict of interest.

**ORCID iD**
Chao Sun \(\text{https://orcid.org/0000-0002-0380-7999}\)

**Supplemental material**
Supplemental material for this article is available online.

**References**
1. Kim G, Kang SH, Kim MY, \textit{et al.} Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. \textit{PLoS One} 2017; 12: e0186990.
2. Hou L, Deng Y, Fan X, \textit{et al.} A sex-stratified prognostic nomogram incorporating body compositions for long-term mortality in cirrhosis. \textit{JPEN J Parenter Enteral Nutr} 2021; 45: 403–413.
3. Dunn MA, Josbeno DA, Tevar AD, \textit{et al.} Frailty as tested by gait speed is an independent risk factor for cirrhosis complications that require hospitalization. \textit{Am J Gastroenterol} 2016; 111: 1768–1775.
4. Deng Y, Lin L, Fan X, \textit{et al.} Incorporation of frailty estimated by gait speed within MELD-Na and the predictive potential for mortality in cirrhosis. \textit{Ther Adv Chronic Dis} 2020; 11: 2040622320922023.
5. Williams GR, Deal AM, Muss HB, \textit{et al.} Frailty and skeletal muscle in older adults with cancer. \textit{J Geriatr Oncol} 2018; 9: 68–73.
6. Tapper EB, Derstine B, Baki J, \textit{et al.} Bedside measures of frailty and cognitive function correlate with sarcopenia in patients with cirrhosis. \textit{Dig Dis Sci} 2019; 64: 3652–3659.
7. Fozouni L, Wang CW and Lai JC. Sex differences in the association between frailty and sarcopenia in patients with cirrhosis. \textit{Clin Transl Gastroenterol} 2019; 10: e00102.
8. Reijnierse EM, Trappenburg MC, Blauw GJ, \textit{et al.} Common ground? The concordance of sarcopenia and frailty definitions. \textit{J Am Med Dir Assoc} 2016; 17: 371 e7–e12.
9. Mijnarends DM, Schols JM, Meijers JM, \textit{et al.} Instruments to assess sarcopenia and physical frailty in older people living in a community (care) setting: similarities and discrepancies. \textit{J Am Med Dir Assoc} 2015; 16: 301–308.
10. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, \textit{et al.} Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. \textit{Age Ageing} 2010; 39: 412–423.
11. Deng Y, Lin L, Hou L, \textit{et al.} A self-reported Frailty Index predicts long-term mortality in hospitalized patients with cirrhosis. \textit{Ann Transl Med} 2020; 8: 1217.
12. Laube R, Wang H, Park L, \textit{et al.} Frailty in advanced liver disease. \textit{Liver Int} 2018; 38: 2117–2128.
13. Hubbard RE and Story DA. Patient frailty: the elephant in the operating room. *Anaesthesia* 2014; 69(Suppl. 1): 26–34.

14. Kang SH, Jeong WK, Baik SK, *et al.* Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. *J Cachexia Sarcopenia Muscle* 2018; 9: 860–870.

15. Carey EJ, Lai JC, Wang CW, *et al.* A multicenter study to define sarcopenia in patients with end-stage liver disease. *Liver Transpl* 2017; 23: 625–633.

16. Kuo SZ, Ahmad M, Dunn MA, *et al.* Sarcopenia predicts post-transplant mortality in acutely ill men undergoing urgent evaluation and liver transplantation. *Transplantation* 2019; 103: 2312–2317.

17. Correa-de-Araujo R, Addison O, Miljkovic I, *et al.* Myosteatosis in the context of skeletal muscle function deficit: an interdisciplinary workshop at the national institute on aging. *Front Physiol* 2020; 11: 963.

18. Bamba S, Inatomi O, Takahashi K, *et al.* Assessment of body composition from CT images at the level of the third lumbar vertebra in inflammatory bowel disease. *Inflamm Bowel Dis* Epub ahead of print 25 November 2020. DOI: 10.1093/ibd/iza306.

19. Cao Q, Xiong Y, Zhong Z, *et al.* Computed tomography-assessed sarcopenia indexes predict major complications following surgery for hepatopancreatobiliary malignancy: a meta-analysis. *Ann Nutr Metab* 2019; 74: 24–34.

20. Kitajima Y, Hyogo H, Sumida Y, *et al.* Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. *J Gastroenterol Hepatol* 2013; 28: 1507–1514.

21. Kitajima Y, Eguchi Y, Ishibashi E, *et al.* Age-related fat deposition in multifidus muscle could be a marker for nonalcoholic fatty liver disease. *J Gastroenterol* 2010; 45: 218–224.

22. Yoshimura T, Suzuki H, Takayama H, *et al.* Impact of prepertative low prognostic nutritional index and high intramuscular adipose tissue content on outcomes of patients with oral squamous cell carcinoma. *Cancers (Basel)* 2020; 12: 3167.

23. Lai JC, Feng S, Terrault NA, *et al.* Frailty predicts waitlist mortality in liver transplant candidates. *Am J Transplant* 2014; 14: 1870–1879.

24. Tandon P, Tangri N, Thomas L, *et al.* A rapid bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: a prospective evaluation of the clinical frailty scale. *Am J Gastroenterol* 2016; 111: 1759–1767.

25. Wijarnpreecha K, Werlang M, Panjawatanan P, *et al.* Association between sarcopenia and hepatic encephalopathy: a systematic review and meta-analysis. *Ann Hepatol* 2020; 19: 245–250.

26. Kahn J, Wagner D, Homfeld N, *et al.* Both sarcopenia and frailty determine suitability of patients for liver transplantation-a systematic review and meta-analysis of the literature. *Clin Transplant* 2018; 32: e13226.

27. Houghton JSM, Nickinson ATO, Morton AJ, *et al.* Frailty factors and outcomes in vascular surgery patients: a systematic review and meta-analysis. *Ann Surg* 2020; 272: 266–276.

28. Cunha AIL, Veronese N, de Melo Borges S, *et al.* Frailty as a predictor of adverse outcomes in hospitalized older adults: a systematic review and meta-analysis. *Ageing Res Rev* 2019; 56: 100960.

29. Souza NC, Gonzalez MC, Martucci RB, *et al.* Frailty is associated with myosteatosis in obese patients with colorectal cancer. *Clin Nutr* 2020; 39: 484–491.

30. Hirota K, Kawaguchi T, Koya S, *et al.* Clinical utility of the liver Frailty Index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma. *Hepatol Res* 2020; 50: 330–341.

31. Bhanji RA, Narayanan P, Moynagh MR, *et al.* Differing impact of sarcopenia and frailty in nonalcoholic steatohepatitis and alcoholic liver disease. *Liver Transpl* 2019; 25: 14–24.

32. Samoylova ML, Covinsky KE, Haftek M, *et al.* Disability in patients with end-stage liver disease: results from the functional assessment in liver transplantation study. *Liver Transpl* 2017; 23: 292–298.

33. Bahat G, Tufan A, Kilic C, *et al.* Prevalence of sarcopenia and its components in community-dwelling outpatient older adults and their relation with functionality. *Aging Male* 2020; 23: 424–430.

34. Rier HN, Jager A, Meinardi MC, *et al.* Severe sarcopenia might be associated with a decline of physical independence in older patients undergoing chemotherapeutic treatment. *Support Care Cancer* 2018; 26: 1781–1789.

35. Duarte-Rojo A, Ruiz-Margain A, Montano-Loza AJ, *et al.* Exercise and physical activity for patients with end-stage liver disease: improving functional
status and sarcopenia while on the transplant waiting list. *Liver Transpl* 2018; 24: 122–139.

36. Kahl KG, Utanir F, Schweiger U, *et al.* Reduced muscle mass in middle-aged depressed patients is associated with male gender and chronicity. *Prog Neuropsychopharmacol Biol Psychiatry* 2017; 76: 58–64.

37. Grinspoon S, Corcoran C, Lee K, *et al.* Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. *J Clin Endocrinol Metab* 1996; 81: 4051–4058.

38. Garcia JM, Li H, Mann D, *et al.* Hypogonadism in male patients with cancer. *Cancer* 2006; 106: 2583–2591.

39. Dirchwolf M and Ruf AE. Role of systemic inflammation in cirrhosis: from pathogenesis to prognosis. *World J Hepatol* 2015; 7: 1974–1981.

40. Soysal P, Stubbs B, Lucato P, *et al.* Inflammation and frailty in the elderly: a systematic review and meta-analysis. *Ageing Res Rev* 2016; 31: 1–8.

41. Toth MJ, Matthews DE, Tracy RP, *et al.* Age-related differences in skeletal muscle protein synthesis: relation to markers of immune activation. *Am J Physiol Endocrinol Metab* 2005; 288: E883–E891.

42. Nishijima TF, Deal AM, Williams GR, *et al.* Frailty and inflammatory markers in older adults with cancer. *Aging (Albany NY)* 2017; 9: 650–664.

43. Lin L, Yang F, Wang Y, *et al.* Prognostic nomogram incorporating neutrophil-to-lymphocyte ratio for early mortality in decompensated liver cirrhosis. *Int Immunopharmacol* 2018; 56: 58–64.

44. Ng TP, Feng L, Nyunt MS, *et al.* Nutritional, physical, cognitive, and combination interventions and frailty reversal among older adults: a randomized controlled trial. *Am J Med* 2015; 128: 1225–1236.e1.

45. Laur CV, McNicholl T, Valaitis R, *et al.* Malnutrition or frailty? Overlap and evidence gaps in the diagnosis and treatment of frailty and malnutrition. *Appl Physiol Nutr Metab* 2017; 42: 449–458.

46. Nachit M and Leclercq IA. Emerging awareness on the importance of skeletal muscle in liver diseases: time to dig deeper into mechanisms! *Clin Sci (Lond)* 2019; 133: 465–481.

47. Ney M, Tangri N, Dobbs B, *et al.* Predicting hepatic encephalopathy-related hospitalizations using a composite assessment of cognitive impairment and frailty in 355 patients with cirrhosis. *Am J Gastroenterol* 2018; 113: 1506–1515.

48. Tapper EB, Konerman M, Murphy S, *et al.* Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index. *Am J Transplant* 2018; 18: 2566–2570.